 |
News
-
The WHO Global Diabetes Compact: an opportunity for lasting change (April 2021)
13 April 2021 - The Global Diabetes Compact is a major new WHO initiative which will unite people working in diabetes prevention, treatment and care, including people living with the condition, around a common agenda. Read More -
Sudarshan Jain takes over the position of IGBA Chair (January 2021)
Geneva, 11 January 2021 - IGBA, the International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA), is taking over the position of… Read More -
IGBA Launches First Global Biosimilars Week (November 2020)
Geneva, November 16, 2020 – Today the International Generic and Biosimilar Medicines Association (IGBA) launched the first ever Global Biosimilars Week, which is aimed at raising the awareness of biosimilar medicines worldwide through a globally aligned educational initiative. Read More -
Innovative and generic & biosimilar pharmaceutical industries unite on commitment to equitable access to COVID-19 medicines and vaccines, while flagging where further help is needed from others (November 2020)
Geneva 10 November 2020 – On the occasion of the World Health Assembly, the world’s research-based and generic & biosimilar pharmaceutical industry bodies delivered a statement declaring their shared commitment to equitable access to COVID-19 medicines and vaccines. In their joint statement,… Read More
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
Vision and Mission
Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.
The IGBA
In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.
The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in September 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).
